The semi-technical view on the two current Eugeroics

Modafinil & Adrafinil - Research and Sources: "Modafinil and Adrafinil are the first of an entirely new class of pharmaceutical - the Eugeroics ('good arousal') - designed to promote vigilance and alertness. This unique class contains only Modafinil and Adrafinil, both of which have been developed by Lafon Laboratories as wake-promoting agents that improve wakefulness. The basis of their uniqueness lies in their ability to stimulate only when stimulation is required. As a result, the 'highs and lows' associated with other stimulants such as amphetamine are absent with Eugeroics. Modafinil and Adrafinil won't prevent a person from sleeping if they want to, but if they wish to remain awake they will do so with a far greater alertness. Numerous clinical trials and studies since the mid 1980's have confirmed the ability of Modafinil and Adrafinil to increase awakeness and alertness without serious side effects or dependency. One of those involved volunteers who were subjected to 60 hours of sleep deprivation. During their continued wakefulness, their vigilance was assessed using questionnaires, visual scales and sleep latency tests. The subjects received either 200 mg Modafinil or a placebo every 8 hours. The Modafinil group sustained a satisfactory level of vigilance with an absence of sleep episodes, unlike the placebo group who gradually declined and slipped into 'micro-sleep' episodes, (as one might expect when awake for longer than 24 hours). Another study conducted over 3 years discovered that Modafinil reduced drowsiness in 83% of hypersomniac patients and 71% of narcoleptics. Modafinil did not produce side effects, disturb night sleep, or promote drug dependence."

smart drugs
eugeroics
Modafinil
Adrafinil